Crescita Therapeutics (CTX) Q4 2024 earnings summary

Executive summary

• Revenue increased to $19.6M for 2024, up 12% year-over-year, driven by growth in Commercial Skincare and Manufacturing segments.

• Net loss widened to $2.8M in 2024 from $2.0M in 2023, reflecting higher SG&A and lower gross profit.

• Q4-2024 revenue rose to $6.9M from $4.7M year-over-year, mainly due to manufacturing reimbursement and higher skincare sales, offset by lower licensing royalties.

• Acquisition of Occy Laboratoire Inc. and Aquafolia assets in 2024 expanded product portfolio and client base.

• Major customer in Manufacturing segment accounted for 25% of total revenue in 2024.

Financial highlights

• Gross profit declined to $9.6M from $10.4M year-over-year, with gross margin dropping to 49% from 59%.

• Operating loss increased to $3.2M from $2.0M, mainly due to higher SG&A expenses.

• Cash and cash equivalents at year-end were $9.3M, nearly unchanged from prior year.

• Adjusted EBITDA for full-year 2024 was $(1.54)M, down from $(368)K.

• Inventory write-downs totaled $258K in 2024, down from $438K in 2023.

Outlook and guidance

• U.S. relaunch of Pliaglis expected in late 2025 under new distribution agreement.

• Management prioritizes cash management and seeks opportunities to enhance revenue and profits.